Predicting Outcomes in Posttransplant Diabetes Mellitus Via microRNA

Launched by UNIVERSITY HOSPITAL, MARTIN · Jun 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how to better predict and detect diabetes that can develop after a kidney transplant, called post-transplant diabetes mellitus (PTDM). Researchers are looking at tiny molecules in the blood, called microRNAs, measured three months after the transplant to see if these can help forecast who might develop diabetes within the next one to two years. They are also examining how other factors like age, medications to prevent organ rejection, body weight, and infections might affect these microRNA markers. The goal is to find early signs of blood sugar problems so doctors can act quickly to improve care and outcomes for kidney transplant patients.

The study is open to adults aged 18 and older who are receiving a kidney transplant and do not already have diabetes. Participants will need to agree to the study and follow its procedures, which may include blood tests to measure microRNAs and regular health check-ups after the transplant. People who have had another organ transplant before, have severe health issues affecting the pancreas, or cannot give informed consent are not eligible. If you or a loved one is about to have a kidney transplant, this study might offer an opportunity to help researchers find better ways to prevent diabetes after transplant and improve long-term health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients undergoing kidney transplantation.
• • Absence of pre-existing type 1 or type 2 diabetes mellitus.
• • Willingness to provide informed consent and comply with study procedures.
• Exclusion Criteria:
• • Pre-existing type 1 or type 2 diabetes mellitus.
• • Previous organ transplantation.
• • Severe comorbidities that could confound the assessment of PTDM (e.g., pancreatic disease).
• • Inability to provide informed consent.